Myasthenia Gravis Disease Treatment Market

Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
Myasthenia Gravis Disease Treatment Market contains market size and forecasts of Myasthenia Gravis Disease Treatment in Global, including the following market information:
Global Myasthenia Gravis Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Myasthenia Gravis Disease Treatment market was valued at 1431.5 million in 2021 and is projected to reach US$ 2051.2 million by 2028, at a CAGR of 5.3% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Medication Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Myasthenia Gravis Disease Treatment include GlaxoSmithKline, Novartis, Teva Pharmaceutical, Roche, Bristol-Myers Squibb, Apotex, Cipla, Biogen and AbbVie, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Myasthenia Gravis Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myasthenia Gravis Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Myasthenia Gravis Disease Treatment Market Segment Percentages, by Type, 2021 (%)
Medication
Surgery
Others
Global Myasthenia Gravis Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Myasthenia Gravis Disease Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Myasthenia Gravis Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Myasthenia Gravis Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Myasthenia Gravis Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Myasthenia Gravis Disease Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
Novartis
Teva Pharmaceutical
Roche
Bristol-Myers Squibb
Apotex
Cipla
Biogen
AbbVie
Bausch Health Companies Inc.
Sun Pharmaceuticals
Fresenius Kabi
Piramal Healthcare
RPG Life Sciences